Antiviral Chemotherapy 5 by John Mills
Scientists and clinicians attending the last New Directions in Antiviral Therapy conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in- cubation period of active HIV infection, when the infection is clinically latent, is now un- derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to be essential tools for monitoring the course of HIV infection, deciding when to treat, and assessing the re- sults of treatment; and finally, combinations of antiretrovirals, particularly combinations including protease inhibitors, have been shown to have dramatically beneficial effects on patients with HIV infection. These advances, coupled with new drugs for the management of herpesvirus infections, have made dramatic differences in the quality and length of life of HIV-infected patients. Additional advances have been made since 1994 in the prevention or management of influenza virus (zanamavir), respiratory syncytial virus (palvizumab), hepatitis B virus (lamivudine and famciclovir), and enterovirus infections (pleconaril). It is difficult to re- member that only slightly more than a decade ago there were only a handful of antiviral agents available (none of which were antiretrovirals), and a number of those were either highly toxic, of dubious efficacy, or both.-
Hot and Cold Theory: The Path Towards Personalized Medicine
-
The Long and Short Non-coding RNAs in Cancer Biology
-
The Immunology of Cardiovascular Homeostasis and Pathology
-
The Hair Fibre: Proteins, Structure and Development
-
Biological Time Control
-
Respiratory Treatment and Prevention
-
Cell Biology and Translational Medicine, Volume 19
-
Advances in Microbiology, Infectious Diseases and Public Health
-
Inflammatory Disorders
-
Visualized Medicine
-
Lung Cancer and Autoimmune Disorders
-
Mass Spectrometry-Based Approaches for Treating Human Diseases and Diagnostics
-
Neurotransmitter Interactions and Cognitive Function
-
Diabetes: from Research to Clinical Practice
-
Cell Biology and Translational Medicine, Volume 21
-
Recent Advances in NGF and Related Molecules
-
Clinical Management of Challenges in Allogeneic Stem Cell Transplant
-
Advances in Biochemistry and Molecular Biology to meet Africa´s Needs
-
Hox Genes
-
Forkhead Transcription Factors
-
Supramolecular Protein Assemblies In Cells
-
Cancer Metabolic Remodeling
-
Proteins
-
Molecular Mechanisms of Spondyloarthropathies
-
Emerging Sample Treatments in Proteomics
-
Reproductive Sciences in Animal Conservation
-
Omics Approaches in Biomedicine and Biotechnology
-
Understanding Depression
| SKU | Unavailable |
| ISBN 13 | 9781461371502 |
| ISBN 10 | 1461371503 |
| Title | Antiviral Chemotherapy 5 |
| Author | John Mills |
| Series | Advances In Experimental Medicine And Biology |
| Condition | Unavailable |
| Binding Type | Paperback |
| Publisher | Springer-Verlag New York Inc. |
| Year published | 2012-10-10 |
| Number of pages | 271 |
| Cover note | Book picture is for illustrative purposes only, actual binding, cover or edition may vary. |
| Note | Unavailable |